Media release

Wayshine Biopharm Announces WSD0628 Received NCI U19 Funding Support Preclinical and Clinical Development

November 22, 2021--Wayshine Biopharm, a clinical-stage pharmaceutical company, today announced that its First-in-Class CNS penetrable radiosensitizer, namely WSD0628, has received U19 grant from the US National Cancer Institute (NCI) to support the preclinical and clinical development. The Glioblastoma Therapeutics Network (GTN) NCI U19 funding was granted to improve the treatment of adult glioblastoma (GBM) by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them in the clinic.

NCI U19 grant is a significant milestone in the WSD0628 development program, commented Dr. Wei Zhong, Ph.D., CEO and Founder of Wayshine Biopharm. We are very pleased that the NCI has granted the funding to support the preclinical and clinical development of WSD0628. The U19 grant by the NCI based on encouraging preclinical data truly reflects our innovation and commitments and the clinical potential of WSD0628 has been recognized and endorsed by the NCI. Thanks NCI scientific review panel, collaborator Mayo Clinic and Yale Medical School’s strong support. The high potency, high selectivity, high brain penetration with good PK, good safety window and significant overall survival prolongation in intracranial pdx models including but not limit to GBM, DIPG and cancers with brain mets when combo WSD0628 with radiation warrant the clinical development of WSD0628. The IND enabling study is ongoing. FDA IND approval and phase I clinical trial are expected in the second half of 2022.

For more information, please visit :NCI-funded Glioblastoma Therapeutics Network (GTN) Will Work Collaboratively to Develop New Treatments | News & Events | DCTD ( 

Copyright © 2018 Wayshine Biopharm International Ltd. Cayman